Pantoprazole Sodium Injections with Yellowish-Brown Powder Recalled
Aurobindo Pharma USA Inc recalls Pantoprazole Sodium 40mg injections with yellowish-brown powder. Discoloration may indicate contamination. Check NDC 55150-202-00 and lot CPO160028.
Lower-risk recall
Discoloration: Some vials were found to contain powder with a yellowish-brownish appearance.
Contact the company
What happened, in plain English
Aurobindo Pharma USA Inc is recalling Pantoprazole Sodium for Injection 40mg vials that show discoloration. This discoloration could indicate contamination, which may pose a health risk if the medication is used. Read more at govinfonow.com/recall/42120-pantoprazole-sodium-injections-with-yellowish-brown-powder-recalled.
Source Summary by GovInfoNow · govinfonow.com/recall/42120-pantoprazole-sodium-injections-with-yellowish-brown-powder-recalled · Updated October 8, 2026 · FDA enforcement record: FDA #D-0470-2017
Cite this page
“Pantoprazole Sodium Injections with Yellowish-Brown Powder Recalled.” GovInfoNow, updated October 8, 2026. https://govinfonow.com/recall/42120-pantoprazole-sodium-injections-with-yellowish-brown-powder-recalled. Based on FDA recall #D-0470-2017 (https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0470-2017%22&limit=1).
Why it’s dangerous
The vials may contain yellowish-brown powder, which could indicate contamination. This discoloration might lead to health issues if the medication is administered without proper quality control.
Who’s affected
Patients prescribed Pantoprazole Sodium for Injection 40mg by a doctor who received the recalled vials (NDC 55150-202-00, lot CPO160028) are affected. Those using the product without medical supervision are not at risk.
How to tell if you have this one
Check for vials with yellowish-brown powder. The product has NDC 55150-202-00 and was manufactured in India for Auromedics Pharma LLC, lot CPO160028, expiring June 2018.
- Brand
Aurobind: Aurobindo Pharma USA Inc- Category
Drug
What to do — step by step
Check Vial Appearance
Look for yellowish-brown powder in the vial. If present, do not use the product.
Where it went and when
Where it was distributed
Distributed nationwide.
FDA distribution: “Nationwide in US” States read from FDA’s own wording; “not listed” means the notice does not name it.
Distributed nationwide.
Recall timeline
FDA terminated this recall 3.6 years after the firm started it.
- Firm started the recall
- FDA classified it Class III
- Published in FDA’s Enforcement Report
- FDA terminated the recall
Dates from the agency record only; steps without a date are left out.
Similar recalls
Other Aurobind: Aurobindo Pharma USA Inc recalls
Latest drug recalls
Keep exploring
Where this comes from
The facts (hazard, remedy, dates, manufacturer) are pulled from the official FDA recall record. The plain-language summary and step-by-step checklist are written by GovInfoNow to make the official notice easier to act on — they don’t replace it.
- Official source: FDA Recall #D-0470-2017 (December 16, 2016) — FDA publishes no per-recall page; this is the official machine-readable enforcement record. Search FDA recalls for D-0470-2017 to see it in context.
- Plain-language summary written by qwen3:4b on October 8, 2026, from the official record above. Not reviewed by a person — if it conflicts with the FDA notice, the notice is correct. Report an error on this page.
- GovInfoNow is an independent service and is not a government agency. We republish official FDA recall data; we don’t issue, amend or administer recalls.